NCT06972498View on ClinicalTrials.gov

A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Colorectal Cancer With Liver Metastasis
Interventions
DRUG

Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.

Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER